Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21439457 | 0.89 | CFD (0.56) | CFDBRD4ROCK2CYP2D6CREBBP | |
| SCHEMBL21455653 | 0.89 | CFD (0.48) | CFDSUCNR1BRD4ROCK2CYP2D6 | |
| SCHEMBL25879818 | 0.87 | CFD (0.64) | CFDCYP2D6L3MBTL1 | |
| Hexane SCHEMBL21545676 | 0.86 | CFD (0.46) | CFDSUCNR1BRD4ROCK2CYP2D6 | |
| SCHEMBL21455667 | 0.83 | CFD (0.69) | CFDSUCNR1BRD4ROCK2CYP2D6 | |
| SCHEMBL31266585 | 0.83 | CFD (0.69) | CFDSUCNR1BRD4ROCK2CYP2D6 | |
| SCHEMBL25879816 | 0.78 | CFD (0.71) | CFDSUCNR1 | |
| SCHEMBL21437981 | 0.76 | CFD (0.63) | CFDSUCNR1 | |
| SCHEMBL24200073 | 0.76 | ACACB (0.40) | CFDBRD4NAMPTCYP1A2L3MBTL1 | |
| SCHEMBL25879808 | 0.74 | BRD4 (0.41) | BRD4CYP2D6CREBBPNAMPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885SUCNR1 2424/4885BRD4 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.